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ABSTRACT
Colon cancer is one of the leading causes of cancer-related death worldwide and the 
WKHUDS\ZLWKÀXRURXUDFLO)8LVPDLQO\OLPLWHGGXHWRUHVLVWDQFH5HFHQWO\ZHKDYH
demonstrated that nucleolar stress upon 5-FU treatment leads to the activation of ribosome-
IUHHUS//DVSURDSRSWRWLFIDFWRU,QWKLVVWXG\ZHDQDO\]HG/H[SUHVVLRQSUR¿OHLQ















In eukaryotes, ribosomal proteins (r-proteins) in 
addition to the role as components of translation machinery, 
exert a variety of extra-ribosomal functions [1–4].
These extraribosomal activities include DNA 
replication transcription and repair; RNA splicing and 
PRGL¿FDWLRQFHOOJURZWKDQGSUROLIHUDWLRQUHJXODWLRQRI
apoptosis and cellular transformation. Some r-proteins 
take part to tumorigenesis by controlling oncogene and 
tumor suppressor expression [5]. 
5HFHQWGDWDVKRZWKDWVRPHUSURWHLQVFDQUHJXODWH
the function of the tumor suppressor p53 [6]. Several 
r-proteins represent additional important component 
RIS DXWRUHJXODWRU\ IHHGEDFN ORRS DQG DUH VKRZQ WR
activate p53 and trigger cell cycle arrest and apoptosis 
[7, 8]. In addition, many r-proteins can themselves 
function as tumor suppressors.
In cancer cell proliferation the rate of ribosome 
SURGXFWLRQ LV HVVHQWLDO WR VXVWDLQ FHOO JURZWK DQG
proliferation suggesting that cancer cells are more 
sensitive to nucleolar stress than normal cells. Thus, 
chemotherapeutic agents that selectively target ribosome 
biogenesis could be less toxic to normal and differentiated 
cells [9]. Many common anticancer drugs as 5-FU interfere 
ZLWKU51$PHWDEROLVPDQGULERVRPHELRJHQHVLV>@7KH
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resulting nucleolar stress causes the accumulation of free 
USURWHLQVZKLFKFDQH[HUWWKHLUH[WUDULERVRPDOIXQFWLRQV
A subset of these ribosome-free proteins activate different 
VLJQDOLQJSDWKZD\VLQFOXGLQJULERVRPDOSURWHLQ0XULQH
'RXEOH0LQXWHSSDWKZD\WRPHGLDWHFHOOF\FOHDUUHVW
apoptosis, differentiation and/or senescence [11]. Although 
WKHVHSDWKZD\VDUHZHOOVWXGLHGPRVWFDQFHUFHOOVFRQWDLQ
PXWDQWSRUQRSDWDOODQGSLQGHSHQGHQWSDWKZD\V
reveal a role of ribosomal proteins in regulation of 
nucleolar stress response [12].
5-FU is commonly used for the treatment of 
FRORQ FDQFHU +RZHYHU LWV DQWLWXPRU DFWLYLW\ LV ORZ
DSSUR[LPDWHO\PDLQO\GXH WR UHVLVWDQFH$JUHDW
GHDORIHIIRUWKDVJRQHLQWRLGHQWLI\LQJQHZFRQWULEXWLQJ
molecules that may enhance tumor response to 5-FU. 
The regulation of drug sensitivity by r-proteins has 
been already documented. To date, rpS3a is involved in 
regulation of cancer cell response to chemotherapy [13]. 
Mitochondrial rpL41 targets the activating transcription 
factor 4 (ATF4), a major regulator of tumor cell survival, 
for degradation contributing to sensitize tumor cells to 
chemotherapy [14].
5HFHQWO\ ZH GHPRQVWUDWHG WKDW ULERVRPHIUHH
rpL3 (L3) represents a crucial player in cell response 
to nucleolar stress induced by 5-FU in colon and lung 
cancer cells devoid of p53 [15]. Apoptosis represents an 
importan event in the treatment of cancer. The success of a 
therapeutic strategy depends mainly on the capacity of the 
drug to induce apoptosis either by inhibiting antiapoptotic 
protein or by stimulating the expression of proapoptotic 
PROHFXOHV5HFHQWO\ZHKDYHGHPRQVWUDWHGWKDWQXFOHRODU
stress upon 5-FU treatment leads to the activation of L3 as 
proapoptotic factor. In particular, L3 regulates  CBS and 
p21 expression at transcriptional and post-translational 
levels leading to cell cycle arrest or apoptosis [16]. 
Our results prompted us to hypothize that the 
NQRZOHGJHRI/VWDWXVLQSQXOOFDQFHUVPD\KDYHD
VLJQL¿FDQWYDOXHLQWHUPVRIWKHHI¿FDF\RIFKHPRWKHUDS\
EDVHG RQ )8 ,Q WKLV VWXG\ ZH GHPRQVWUDWH WKDW /
H[SUHVVLRQLQFRORQWXPRUWLVVXHVLVGRZQUHJXODWHG/
P51$GHFUHDVHDVVRFLDWHGZLWKPDOLJQDQFHSURJUHVVLRQ
DQG WXPRUJUDGHDQGZDV LQYHUVHO\SURSRUWLRQDO WR WKH
ratio Bcl-2/Bax; L3 overexpression in 5-FU treated colon 
cancer cells decreased clonogenic potency, cell migration 
and cell viability, and stimulated apoptotic cell death by 
inducing late apoptosis. The potential of this strategy 
IRUWKHWUHDWPHQWRIFRORQFDQFHUZDVQH[WLQYHVWLJDWHG
by using novel polymeric nanoparticles based on a core 
of poly(lactic-co-glycolic) acid (PLGA) and a polymer 
shell of Hyaluronan (HA) and Polyethyleneimine (PEI) 
as platform to deliver the 5-FU and the proapoptotic 
protein L3 [17, 18]. Combined NP treated cells exhibited 
HI¿FLHQWFHOOXODUXSWDNHDQGH[SUHVVKLJKDQGSURORQJHG
levels of L3 protein and its target p21. Combined NP 
treatment resulted more effective in inducing apoptosis 
LQ FDQFHU FHOOV WKDQ)8RU/DORQH ,QDGGLWLRQZH
demonstrated that cytotoxic effect of combined NPs 
ZDVGXHWRWKHDELOLW\RI/WRGHVWDELOL]H0'50XOWL
'UXJ 5HDFWLYLW\  P51$ DQG GRZQUHJXODWH 3JS
3JO\FRSURWHLQSXPSH[SUHVVLRQLQKLELWLQJLQWKLVZD\
)8HIÀX[IURPWUHDWHGFHOOV
Altogether these results led us to propose a novel 
FRPELQHGWKHUDS\ZLWKWKHXVHRI)8DORQJZLWKS/LQ
order to establish individualized therapy by examining L3 
DQGSSUR¿OHVLQSDWLHQW¶VWXPRUVZLWKWKHH[SHFWDWLRQ






to assess the expression of L3 and its target gene p21, 
%FODQG%D[DWWKHP51$OHYHOVLQFRORQFDQFHUV
and normal tissues. Comparison of human colon cancer 
VSHFLPHQVZLWKSDWLHQWPDWFKHGQRUPDOWLVVXHVUHYHDOHG
WKH GRZQUHJXODWLRQ RI / LQ WXPRUV$V DWWHQGHGZH




tumor grade (Figure 1B, 1C). 
Table 1 summarizes demographic, pathological and 
clinical data of analyzed tissues. 
/HQKDQFHV)8PHGLDWHGLQKLELWLRQRIFHOO
YLDELOLW\FORQRJHQLFLW\DQGPLJUDWLRQ
7KH DQDO\VLV RI / H[SUHVVLRQ SUR¿OH LQ WXPRUV
SURPSHWHGXVWRLQYHVWLJDWHZKHWKHUWKHXSUHJXODWLRQRI
L3 may potentiate the cytotoxic activity of 5-FU. We have 
previously demonstrated that L3 may induce G1/S cell 
cycle arrest or apoptosis depending on its concentration 
inside the cell [19]. With the aim of examining the 
combined effect of L3 and 5-FU on cell viability, HCT 
116SííFHOOVDQGUS/¨+&7Síícells, a cell line stably 
GHSOHWHGRI/>@ZHUHWUDQVLHQWO\WUDQVIHFWHGZLWKD
pro-apoptotic concentration of a plasmid encoding L3-GFP 
IXVLRQ SURWHLQ S/  ȝJ DQG WUHDWHG RU QRW ZLWK D
VXEWR[LF GRVH RI )8  ȝ0  K  K  K DQG
 K ODWHU FHOO YLDELOLW\ZDV HVWLPDWHG E\077 DVVD\
As expected, the percentage of cell viability decreased 
after 5-FU treatment or pL3 transfection compared to 
untreated HCT 116Síícells, control. Of note, in cells 
WUDQVIHFWHGZLWKS/DQGWUHDWHGZLWK)8ZHIRXQGWKDW
WKHFHOOYLDELOLW\ZDVVWURQJO\UHGXFHGFRPSDUHGZLWKFHOOV
H[SRVHG WR )8 RU WUDQVIHFWHGZLWK S/ )LJXUH $
,Q US/¨+&7 Síí cells, L3 silencing completely 
abolished the cytotoxicity of 5-FU treatment (Figure 2B). 
1HYHUWKHOHVV WKLV HIIHFW ZDV GLUHFWO\ UHVFXHG E\ S/
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WUDQVIHFWLRQ)LJXUH%FRQ¿UPLQJWKHFUXFLDOUROHRIWKLV





treatment on cell proliferation by performing a clonogenic 
assay. To this aim, HCT 116SííDQGUS/¨+&7Síí
FHOOVZHUHSUHWUHDWHGZLWKȝ0)8IRUKWKHQ
WUDQVLHQWO\ WUDQVIHFWHG ZLWK  ȝJ RI S/ )LJXUH &
VKRZV D UHGXFWLRQ RI FRORQ\ QXPEHU RI +&7 Síí 
FHOOVXSRQH[SRVXUHWR)8FRQ¿UPLQJWKHDELOLW\RIWKH
GUXJWRLQKLELWFORQRJHQLFLW\7KHFDSDFLW\RIUS/¨+&7
116Síícells to produce colonies upon 5-FU treatment 
ZDVFRPSDUDEOHWRWKDWRIXQWUHDWHGFHOOVFRQ¿UPLQJWKDW
the loss of L3 plays an important role in the inhibition of 
FHOOSUROLIHUDWLRQXSRQH[SRVXUHWR)8,WLVQRWHZRUWK\
that in both cell lines pL3 transfection and 5-FU treatment 
UHVXOWHGLQDIXUWKHUUHGXFWLRQRIFORQRJHQLFLW\FRQ¿UPLQJ
the ability of L3 to improve the cytotoxic activity of 5-FU. 
7KHHIIHFWRIUS/RQFHOOYLDELOLW\DQGFORQRJHQLFLW\ZDV
FRQ¿UPHGLQ+7FHOOVDQRWKHUKXPDQFRORQFDQFHUFHOO
line non harboring p53 (Supplementary Figure S1). 
)XUWKHUPRUH ZH LQYHVWLJDWHG WKH UROH RI /
RYHUH[SUHVVLRQ DORQH RU LQ FRPELQDWLRQZLWK )8 RQ




Figure 2D, the migration ability of 5-FU treated HCT 
116SííFHOOVZDVUHGXFHGRIDERXWDQGDW
KDQGKUHVSHFWLYHO\DVFRPSDUHGZLWKXQWUHDWHGFHOOV
VHW DV  FRQWURO:KHQ US/ ZDV RYHUH[SUHVVHG
the migration ability of 5-FU treated HCT 116Síí cells 
ZDV IXUWKHU UHGXFHG  DQG  DW  K DQG  K
UHVSHFWLYHO\ YV XQWUHDWHG FHOOV VHW DV  FRQWURO
GHPRQVWUDWLQJWKDW/RYHUH[SUHVVLRQZDVDEOHWRLPSURYH
5-FU mediated inhibition of cell motility. Additionally, 
ZHGHPRQVWUDWHG WKDW LQKLELWLRQRI FHOOVPLJUDWLRQZDV
VSHFL¿FDOO\PHGLDWHGE\/)RUWKLVSXUSRVHDQDORJRXV
H[SHULPHQWV ZHUH SHUIRUPHG LQ US/¨+&7 Síí
cells. In this cell line, 5-FU treatment failed to inhibit 
cell migration; of note, the transfection of pL3 together 
ZLWK)8 WUHDWPHQWZHUHDEOH WR UHVFXH)8DFWLYLW\
)LJXUH(DQG6XSSOHPHQWDU\)LJXUH64XDQWL¿FDWLRQ
of migrated cell number indicated that the overexpression 
)LJXUH([SUHVVLRQSUR¿OHRI/S%D[DQG%FO LQQRUPDOFRORQ WXPRU WLVVXHVDQGFRORQDGHQRFDUFLQRPD 
T573&5 GDWD VKRZLQJ A / S %FO DQG%D[P51$ OHYHOV LQ WXPRU WLVVXHV SDLUHGZLWK WKH QRUPDOPXFRVD WLVVXHV VHW DV  
(B) L3 mRNA levels and (C%FO%D[UDWLRDPRQJGLIIHUHQWJURXSVRIJUDGH17QRQWXPRUWLVVXH5HVXOWVDUHVKRZQDVIROGFKDQJH
(mean ± SEM) (n = 3) of normal mucosa tissues set as 1. Results illustrated in Figures 1–8, are representative of three independently 







E\ LQGXFLQJ DSRSWRVLV ZH DQDO\]HG WKH UHGXFWLRQ RI
PLWRFKRQGULDO LQQHU PHPEUDQH SRWHQWLDO ǻȌP E\
tetramethyl-rhodamine ethyl ester (TMRE) staining, 






in each cell line. 
To ascertain the above observation, Annexin V analysis 
ZDVSHUIRUPHG+&7SííFHOOVZHUHWUDQVIHFWHGZLWK
ȝJRIS/WUHDWHGZLWK)8IRUKDQGWKHQHYDOXDWHG
ZLWK $QQH[LQ 9),7& $V VKRZQ LQ )LJXUH & WKH
percentage of cells Annexin V positive increased after 5-FU 
treatment and pL3 transfection compared to cells untreated 
RUWUHDWHGZLWK)8RUS/DORQH
7KHVH UHVXOWVZHUH IXUWKHU FRQ¿UPHGE\$QQH[LQ
9),7&3, GXDO VWDLQLQJ 6SHFL¿FDOO\ ZH IRXQG WKDW
S/ WUDQVIHFWLRQ VLJQL¿FDQWO\ LQFUHDVHG WKH SHUFHQWDJH
of late apoptotic cells (Annexin V+ and PI+ IURP
LQ WKH XQWUHDWG FHOOV WR  LQ S/WUDQVIHFWHG FHOOV
)LJXUH)XUWKHUPRUH LQDJUHHPHQWZLWKFHOOJURZWK
inhibition, the combination treatment of pL3 plus 5-FU 
ZDVDEOHWRUHGXFHWKHQXPEHURIQHFURWLFFHOOVLQGXFHG
by 5-FU treatment alone and to induce a higher number 
of Annexin V+ and PI+ cells, i.e. apoptotic cells, than the 
7DEOH'HPRJUDSKLFSDWKRORJLFDODQGFOLQLFDOGDWDRIDQDO\]HGWLVVXHV
Case n° Gender Age 'LIIHUHQWLDWLRQ Grade Stage
1 Female 72 Moderate G2 pT2 pNO
2 Female 81 Moderate in situ G2/3 pTis pNO
3 Female 38 Poor G2 pT2 pN1a
4 Female 58 Moderate, Ulcerated G2 pT2 pNO
5 Female 66 Poor G2/3 ypT2 ypN1b
6 Male  Moderate G2 pT2 pNO
7 Male 67 Poor, Mucinous G3 pT3 pNO
8 Male  Poor, Ulcerated G3 pT4b pN1b
9 Male 56 Moderate G2 pT2 pNO
 Male 48 Moderate G2 pT2 pNO
11 Male 51 Moderate, Mucinous G2 pT2 pNO
12 Male 78 Moderate, Ulcerated G2 pT3 pN1a
13 Male 72 Poor, Mucinous G2/3 pT3 pN2a
14 Female 82 Moderate, Mucinous G2 pT2 pNO
15 Male 73 Moderate, Ulcerated G2 pT2 pN1a
16 Male 67 Moderate G2 pT2 pNO
17 Male 47 Poor G3 pT3 pN2b
18 Male 62 Moderate, Ulcerated G2 pT3 pN2b
19 Male 85 Moderate, Mucinous G2 pT2 pNO
 Male 57 Moderate G2 pT3 pNO
21 Female 78 Moderate G2 pT2 pNO
22 Male 78 Moderate G2 pT2 pNO
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WUHDWPHQWZLWK)8RUS/DORQH)LJXUH$OOWRJHWKHU
these results strongly suggest that the ectopic expression 
RI/DOORZHGDPRUHSRWHQWF\WRWR[LFHIIHFWRI)8RQ
colon cancer cells. On this basis, delivery of pL3/5-FU 




Multistep preparation of combined NPs (Figure 5A) 
comprised: i) the preparation of a negatively-charged 
PLGA nanocore entrapping 5-FU; ii) the adsorption 
)LJXUH  5ROH RI / RQ FHOO YLDELOLW\ FHOO SUROLIHUDWLRQ DQGPLJUDWLRQ XSRQ )8 WUHDWPHQW (A) HCT 116Sííand 
(BUS/¨+&7SííFHOOVZHUHWUDQVLHQWO\WUDQVIHFWHGZLWKS/DQGWUHDWHGZLWK0)8IRUKKKDQGKRUXQWUHDWHG
7KHQFHOOYLDELOLW\ZDVHYDOXDWHGXVLQJ077DVVD\7KHFHOOYLDELOLW\ IURPXQWUHDWHGFHOOVZDVVHW WR5HVXOWVDUHSUHVHQWHGDV
percentage (mean ± SEM) (n = 3) of the control cells. (C) Representative image of clonogenic analysis for cell proliferation in HCT 116Síí
DQGUS/¨+&7SííFHOOVXSRQ/RYHUH[SUHVVLRQDQG)8WUHDWPHQWIRUK$IWHUGD\VFRORQLHVZHUHVWDLQHGZLWKPHWK\OHQH
blue, photographed and counted. (D) HCT 116SííDQG(US/¨+&7SííFHOOVZHUHWUDQVLHQWO\WUDQVIHFWHGZLWKS/DQGWUHDWHGZLWK
0)8IRUKDQGKRUXQWUHDWHG7KHQPLJUDWLRQRIFHOOVZDVH[DPLQHGXVLQJ%R\GHQFKDPEHU&HOOPLJUDWLRQRIXQWUHDWHGFHOOV
ZDVVHWWR5HVXOWVDUHSUHVHQWHGDVSHUFHQWDJHPHDQ6(0n = 3) of the control cells.
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of a cationic PEI layer (PLGA@PEI nanocore); iii) the 
adsorption of pL3 onto PLGA@PEI nanocore; iv) the 







previously reported [18]. To load the plasmid, different 
DPRXQWVRIS/ZHUHLQFXEDWHGZLWK3/*$#3(,QDQRFRUH
GLVSHUVHGLQZDWHUDQGHIIHFWLYHO\DGVRUEHGRQWKHVXUIDFH
(Supplementary Table S2). Then, pL3 adsorption, mean 
hydrodynamic diameter and PI did not change up to 
D FRQFHQWUDWLRQ RI  PJP/ ZKHUH D PDFURVFRSLF
aggregation occurred (Supplementary Table S2). In a 
separate experiment aimed at evaluating the association of 
S/WR3/*$#3(,QDQRFRUHV(W%UÀXRUHVFHQFHHPLVVLRQ
GXHWRS/LQWHUFDODWLRQZDVPRQLWRUHG,WZDVIRXQGWKDW
the emission of EtBr/pL3complex progressively decreased 
)LJXUH5ROHRIUS/RQDSRSWRVLVXSRQ)8WUHDWPHQW(A) HCT 116Síí and (BUS/¨+&7SííFHOOVZHUHWUDQVLHQWO\
WUDQVIHFWHGZLWKS/DQGWUHDWHGZLWK0)8IRUKRUXQWUHDWHG7KHQFHOOVZHUHDQDO\]HGIRUPLWRFKRQGULDOPHPEUDQHSRWHQWLDO
E\705(VWDLQLQJ)OXRUHVFHQFHZDVPHDVXUHGE\ÀRZF\WRPHWU\5HVXOWVDUHSUHVHQWHGDVSHUFHQWDJHRIWKHFRQWUROFHOOVVHWDV
Results are presented as percentage (mean ± SEM) (n = 3) of the control cells. (C) HCT 116SííFHOOVZHUHWUDQVLHQWO\WUDQVIHFWHGZLWKS/
DQGWUHDWHGZLWK0)8IRUK7KHQFHOOGHDWKZDVDVVHVVHGE\)$&6DQDO\VLVRI$QQH[LQ9VWDLQLQJ4XDQWLWDWLYHGDWDDUHUHSRUWHG
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at increasing concentrations of PLGA@PEI nanocores, 
due to hampered intercalation of EtBr to pL3 adsorbed 
onto NPs (Figure 5B). Upon pL3 adsorption, NP zeta 
SRWHQWLDOZDVVWLOOSRVLWLYH6XSSOHPHQWDU\7DEOH6GXH




To evaluate the effective association and protection 











HA did not alter the association extent of pL3 to NPs.
2QWKLVEDVLVZHSUHSDUHGFRPELQHG13VZLWKGLIIHUHQW
5-FU/pL3 reciprocal amounts and evaluated their properties 
(Table 2 and Supplementary Table S2). Final NPs decorated 
ZLWKD+$OD\HUZHUHEHORZQPZLWKDQHJDWLYH]HWD






reciprocal amount of both 5-FU and pL3 by adjusting the 
H[SHULPHQWDO FRQGLWLRQV DQG ZLWKRXW DOWHULQJ WKH RYHUDOO
properties of NPs relevant for biological applications.
)LJXUH$QDO\VLVRIDSRSWRVLVVWDWXVXSRQFRPELQHGWUHDWPHQW)8/HCT 116SííFHOOVZHUHWUDQVLHQWO\WUDQVIHFWHGZLWK
pL3 DQGWUHDWHGZLWK0)8IRUK7KHQFHOOGHDWKZDVDVVHVVHGE\)$&6DQDO\VLVRI$QQH[LQ9DQG3,VWDLQLQJA) Representative 
dot plots and (BTXDQWLWDWLYHGDWDDUHUHSRUWHG
Oncotarget8www.impactjournals.com/oncotarget
5HOHDVH SUR¿OH RI )8 DQG S/ IURP13V ZDV
assessed indirectly from the amount remaining in the NPs 




a similar behavior for PLGA/PEI-NP [21]. 5-FU release 
ZDVVXVWDLQHGDQGDURXQGRIWRWDOGUXJFRQWHQWZDV
released after 6 h.
In vitroDFWLYLW\RI)813S and pL3+13VLQ
+&7SííFHOOV
The cytotoxicity of 5-FU NPs in HCT 116 Síí
FHOOVZDVSUHOLPLQDU\WHVWHG7RWKLVDLP+&7Síí
FHOOV ZHUH WUHDWHGZLWK DZLGH UDQJH RI FRQFHQWUDWLRQV
± ȝ0 RI )8 NPs and in vitro cytotoxicity 
ZDVHYDOXDWHGDIWHUKDQGKRIH[SRVXUHE\XVLQJ
077DVVD\DQGFRPSDUHGWRWKDWRIIUHH)8$VVKRZQ
LQ 6XSSOHPHQWDU\ )LJXUH 6 D VLJQL¿FDQW GHFUHDVH LQ
the IC ZDV REVHUYHG LQ FHOOV WUHDWHG ZLWK )8 13V
either at 72 h or 96 h (ICȝ0DQGȝ0UHVSHFWLYHO\
FRPSDUHG WR FHOOV WUHDWHG ZLWK IUHH )8 ,&  ȝ0
DQGȝ0UHVSHFWLYHO\7KHVHUHVXOWVVXJJHVWWKDW13V
enhanced the cytotoxic activity of 5-FU in HCT 116Síí
cells. To investigate CD44-mediated delivery of NPs, 
CD44 receptor-overexpressing HCT116 Síí FHOOVZHUH
LQFXEDWHGZLWKÀXRUHVFHQW13VODEHOHGZLWK5KRGDPLQH
(pL3H/RhoNPs) from 24 h to 72 h and observed under 
WKH PLFURVFRSH $V VKRZQ LQ )LJXUH $ DQG % WKH
LQFXEDWLRQRIFHOOVZLWKS/H5KR13VOHDGWRDQHI¿FLHQW
and prolonged expression (until 72 h) of L3-GFP in HCT 
)LJXUH  6WUXFWXUH DQG FKDUDFWHUL]DWLRQ RI 13V GHOLYHULQJ )8S/ (A) Sketched representation of NPs delivering 
5-FU+pL3. (B(PLVVLRQVSHFWUDH[FLWDWLRQ QPRIHWKLGLXPEURPLGHLQWKHSUHVHQFHRIS/ORDGHG3/*$#3(,±JP/
(C*HOUHWDUGDWLRQDVVD\EHIRUHDQGDIWHUVDPSOHWUHDWPHQWZLWK'1$VHIUHHS/DS/ORDGHG3/*$#3(,ES/ORDGHG+$FRDWHG
3/*$#3(,FS/ZDVJP/D) Size distribution of the sample during the layering procedure. (E5HOHDVHSUR¿OHRI)8DQG
pL3 from combined NPs in DMEM FBS+.
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116Síícells. Moreover, to better characterize the ability 




Figure S4). Comparing results in Figure 6, panel A and 
Supplementary Figure S4 both NP and Lipo mediated 
transfection lead to an expression of L3-GFP in tumor 
cells. Of note, NPs drastically enhanced transfection 
HI¿FLHQF\ ,Q IDFW FHOOV WUDQVIHFWHGZLWK S/H/RhoNPs 
VKRZHGDVXVWDLQHGDQGDPRUHHI¿FLHQWH[SUHVVLRQRI/
GFP as a function of time. In fact, the results demonstrated 
WKDW WKHUH ZDV D VLJQL¿FDQW LQFUHDVH LQ ÀXRUHVFHQFH
LQWHQVLW\DWKWLPHSRLQWVXJJHVWLQJWKHVORZUHOHDVHRI
DNA from NPs localized inside the cells. In contrast, Lipo 
failed to mantain high expression levels of L3-GFP over 
time (Supplementary Figure S4). These data suggest that 
HYHQWVGRZQVWUHDPRI13LQWHUQDOL]DWLRQDVLQWUDFHOOXODU
WUDI¿FNLQJ XSWDNH DQG SURFHVVLQJ PD\ EH DGGLWLRQDO
GHWHUPLQDQWVRI13PHGLDWHG/H[SUHVVLRQHI¿FLHQF\
)XUWKHUPRUHÀXRUHVFHQFHLQWHQVLW\ZDVVLJQL¿FDQWO\
GHFUHDVHG ZKHQ WKH &' UHFHSWRU ZDV EORFNHG E\
SUHWUHDWPHQWZLWKIUHH+$)LJXUH%&LQGLFDWLQJWKDW
HA-coated NPs can target tumor cells through receptor-




To investigate the cytotoxic activity of the 5-FUH/
pL3HNPs as potential targeted tumor therapy, the inhibitory 
HIIHFWVRIGLIIHUHQWFRPELQDWLRQVRI/DQG)8ZHUH
FRPSDUHGZLWKVLQJOHWUHDWPHQWVLQ+&7Síícells by 
MTT assay. We have previously demonstrated that L3 may 
induce G1/S cell cycle arrest or apoptosis depending on its 
concentration inside the cell [19]. Thus, in combination 
WUHDWPHQW  0 )8 ZDV DSSOLHG DORQJ ZLWK WZR
GLIIHUHQWDPRXQWVRIS/JHJFRUUHVSRQGLQJWR
the cytostatic and the cytotoxic dose, respectively [19]. 
7KHUHVXOWVRIWKHFHOOYLDELOLW\ZLWKGLIIHUHQWWUHDWPHQWV
REWDLQHGDIWHUKDQGKRILQFXEDWLRQZHUHVKRZQ
in Figure 7A. Unloaded NPs exhibited no toxicity at 
tested concentrations and time points. As attended, the 
WUHDWPHQWRIFHOOVZLWKRIS/IUHHRUORDGHGRQWR13V 
(pL3L or pL3L13V UHVSHFWLYHO\ H[KLELWHG DERXW 
DQG  RI FHOO YLDELOLW\ LQKLELWLRQ DW  K DQG  K
UHVSHFWLYHO\ YV XQWUHDWHG FHOOV VHW DV  FRQWURO




RI S/ZDV ORDGHG RQWR13V S/LNPs). Combination 
WUHDWPHQW RI  0 )8ZLWK PJ RU PJ RI S/ 
(5-FUH/pL3LNPs or 5-FUH/pL3HNPs, respectively) 
JHQHUDWHG VLJQL¿FDQWO\ KLJKHU DQWLSUROLIHUDWLRQ HIIHFWV
compared to either agent alone (pL3 or 5-FU). Of note, 
WKH WUHDWPHQW RI FHOOV ZLWK )8H/pL3H13V VKRZHG
PXFKORZHUFHOOYLDELOLW\FRPSDUHGWRWKDWREVHUYHGE\
LQFXEDWLQJFHOOVZLWK)8H/pL3LNPs indicating a strong 
potential for the combination treatment carrying higher 
experimented amount of pL3. In fact, FUH/pL3HNP treated 
cells enhanced the cytotoxicity of 5-FU in HCT 116Síí 
FHOOVE\DERXWFRPSDUHGWR)8DORQHLQGLFDWLQJ
WKDWWKLVFRPELQDWLRQRI/ZLWK)8PLJKWEHSURPLVLQJ
With the aim of further examinin the combined 




treated cells resulted in an enlarged proportion of cells in 




All together these results demonstrate the potential 




upon 5-FUH/pL3H13V WUHDWPHQW ZDV IXQFWLRQDO LQ WKH
induction of its target gene p21, protein extracts from 




the over-expression of L3 associated to a time dependent 
increase of p21 protein amount. In addition, to explore 
alterations in P-gp expression, an ATP-dependent 
membrane transport protein highly expressed in 5-FU 
UHVLVWDQWFDQFHUFHOOV>@WKHH[SUHVVLRQSUR¿OHRI3JS
ZDVDVVHVVHGLQWKHVHFRQGLWLRQV:HVXUSULVLQJO\IRXQG
that P-gp protein level decreased in a time dependent 
manner upon 5-FUH/pL3HNP treatment (Figure 8A). 
The level of MDR1 mRNA expression is an important 
GHWHUPLQDQWRI3JSH[SUHVVLRQOHYHOV7KXVZHGHWHFWHG




IRU0'5 DQG ȕDFWLQ DV FRQWURO 7KH UHVXOWV VKRZHG
that 5-FUH/pL3H13WUHDWPHQWVLJQL¿FDQWO\GHFUHDVHGWKH
amount of MDR1 transcript (Figure 8B). To evaluate the 
importance of L3 in the alteration of MDR1 mRNA level, 
DQDORJRXV H[SHULPHQWV ZHUH SHUIRUPHG LQ US/¨+&7
116Síí.cells. The results demonstrated that the silencing 
RI/ZDVDVVRFLDWHGWRDVWURQJLQFUHDVHRI0'5P51$
OHYHO)LJXUH%1H[WZHLQYHVWLJDWHGZKHWKHU)8H/
pL3HNP treatment could affect MDR1 mRNA half-life. To 
WKLVDLPFHOOVZHUHLQFXEDWHGZLWKFRPELQHG13VIRUK 
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DIWHU ZKLFK WKH WUDQVFULSWLRQ LQKLELWRU$FWLQRP\FLQ ' 
$FW' ZDV DGGHG IRU WKH IROORZLQJ  K WR LQKLELW
QDVFHQW51$V\QWKHVLV7RWDO51$ZDVREWDLQHGIURPWKH
samples at the indicated times (4 h, 8 h, 16 h and 24 h) 
DQG0'5DQGȕDFWLQP51$OHYHOVZHUHDQDO\]HGE\
T573&57KHUHVXOWVVKRZWKDWWKHKDOIOLIHRI0'5
P51$ ZDV GHFUHDVHG IURP DSSUR[LPDWHO\  K LQ
normal HCT 116Síícells to less than 8 h in NP-treated 
FHOOV)LJXUH&7KHVHUHVXOWVLQGLFDWHWKDWWKHGRZQ
UHJXODWLRQRI0'5P51$OHYHOVIROORZLQJ13WUHDWPHQW
could be due in part to a decrease in mRNA stability.
DISCUSSION




DSSOLFDWLRQ RI )8 LV OLPLWHG E\ LWV SRRU VSHFL¿FLW\
ORZELRDYDLODELOLW\DQGVHULRXVGUXJUHODWHGVLGHHIIHFWV
In particular, the main cause of failure in colon cancer 
therapy is represented by the insurgence of resistance 
to 5-FU  in the course of treatment [24]. To overcome 
WKHVH OLPLWDWLRQVQHZ WKHUDSHXWLF VWUDWHJLHVDQGRUQHZ
adjuvant drugs need to be explored. Colon cancer has been 
DVVRFLDWHGZLWK DOWHUDWLRQV LQ DSRSWRVLV UHJXODWLRQ >@
and, in particular, the inhibition of apoptosis is a crucial 
element in carcinogenesis of colorectal cancer as other 
human malignancies [26]. Unlike necrosis, apoptosis is an 
important cell death mechanism that does not trigger an 
LQÀDPPDWRU\UHVSRQVHOHDGLQJWRFROODWHUDOGHVWUXFWLRQRI
normal cells in the surrounding microenvironment [27]. 
&DQFHU FHOOV KRZHYHU H[KLELW UHVLVWDQFH WR DSRSWRVLV
in order to sustain their uncontrolled proliferation and, 
therefore, any apoptosis-modulating compound is 
desirable as a plausible chemotherapeutic agent against 
)LJXUH  &HOOXODU XSWDNH RI S/+5KR13V 5HSUHVHQWDWLYH ÀXRUHVFHQW PLVFURVFRS\ LPDJHV RI +&7 Síí FHOOV WUHDWHG ZLWK 
pL3H5KR13VIRUKKDQGK'DSLZDVXVHGDVDQXFOHDUVWDLQVKRZQLQEOXH/*)3DQG13GHSHQGHQWÀXRUHVFHQFH5KRDUHVKRZQ
in green and red, respectively. The CD44 receptor of HCT 116SííFHOOVZDVEORFNHGZLWKIUHH+$KEHIRUHWUHDWPHQWZLWKQDQRSDUWLFOHV
4XDQWL¿FDWLRQRIÀXRUHVFHQFHLQWHQVLW\LVVKRZQ5HVXOWVDUHSUHVHQWHGDVSHUFHQWDJHPHDQ6(0n RIWKHFRQWUROFHOOVVHWDV
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cancer [28]. In particular, the restoration of signaling 
SDWKZD\V LQYROYHG LQ DSRSWRVLV LQGXFWLRQ EDVHG RQ
targeted multitherapy, may result in improved response to 
)8WUHDWPHQWZKLFKWUDQVODWHVLQWRGHFUHDVHGUHVLVWDQFH
WRFDQFHUWKHUDS\,QWKHSUHVHQWVWXG\ZHGHPRQVWUDWH
the potentiation of the cytotoxic effect of 5-FU on human 
colon cancer cells by proapoptotic L3 and aimed to a 
FRPELQHGWKHUDS\ZLWKWKHXVHRI)8DORQJZLWKF'1$
encoding L3 in order to establish individualized combined 
WKHUDS\ E\ H[DPLQLQJ/ DQG S SUR¿OHV LQ SDWLHQW¶V
WXPRUV ZLWK WKH H[SHFWDWLRQ WR \LHOG D EHWWHU FOLQLFDO
outcomes. 
L3 is a component of the large subunit of 
F\WRSODVPLF ULERVRPHV+RZHYHU LW IXQFWLRQVQRWRQO\
ZLWKLQWKHULERVRPHSDUWLFLSDWLQJLQWUDQVODWLRQEXWDOVRDV
an extraribosomal player involved in a number of cellular 
HYHQWV/DXWRUHJXODWHVLWVRZQH[SUHVVLRQWKURXJKWKH
association of alternative splicing and nonsense-mediated 
)LJXUH(IIHFWRI)8+S/+13VRQFHOOYLDELOLW\DQGFHOOF\FOHLQ+&7SííFHOOV(A) HCT 116SííZHUHWUHDWHGZLWK
JRIHPSW\YHFWRUXQORDGHG13V0)8ORDGHGRQWR13V)8HNPs), 1 mg or 2 mg of free pL3 (pL3L or pL3H, respectively), 
JRUJRIS/ORDGHGRQWR13VS/LNPs or pL3H13VUHVSHFWLYHO\0)8SOXVJRUJRIS/ORDGHGRQWR13V)8H/
pL3LNPs and 5-FUH/pL3H13VUHVSHFWLYHO\IRUKDQGK$IWHULQFXEDWLRQFHOOYLDELOLW\ZDVHYDOXDWHGXVLQJWKH077DVVD\7KHFHOO
YLDELOLW\ IURPXQWUHDWHGFHOOVZDV VHW WRFRQWURO5HVXOWV DUHSUHVHQWHGDVSHUFHQWDJH PHDQ6(0 n = 3) of the control cells. 




promoting or inhibiting the alternative splicing of L3 pre-
mRNA include hnRNP H1, Sp1 and NPM [29]. The action 
of ribosome free L3 has been intensively studied by us and 
the results highlighted its favourable anticancer potential 
over different conventionally used chemotherapeutic 
GUXJVDV/2+3$FW'DQG)8>@,QSDUWLFXODU
RXUVWXGLHVKDYHVKRZQWKDW/UHJXODWHVWUDQVFULSWLRQRI
many genes in response to 5-FU induced nucleolar stress 
>@$NH\H[WUDULERVRPDOUROHRI/LVWREORFNFHOO
cycle progression and/or to induce apoptosis in response 
to drug-induced nucleolar stress. L3 can induce G1 arrest 
through the activation of the cyclin-dependent kinase 
inhibitor p21 transcription and apoptosis by molecular 
SDWKZD\V LQYROYLQJ S DQG &%6 >@ $QDO\VLV RI
/ P51$ H[SUHVVLRQ SUR¿OH GHPRQVWUDWHV WKDW / LV
)LJXUH)8+S/+13WUHDWPHQWQHJDWLYHO\UHJXODWHV3JSH[SUHVVLRQDQG0'5P51$VWDELOLW\(A) Representative 








implicated in colon cancer (Figure 1A). In particular, the 
H[SUHVVLRQRI/LQFRORQFDQFHUSDWLHQWVZDVDVVRFLDWHG
WR DQ DGYDQFHG WXPRU VWDJH )LJXUH % ,Q IDFW ZH
IRXQGWKDW/P51$DPRXQWGHFUHDVHGZLWKPDOLJQDQW
SURJUHVVLRQ DQG WKH LQWHQVLW\ RI LWV H[SUHVVLRQ ZDV
inversely related to tumor grade, possibly suggesting that 
alterations in L3 expression promote tumor progression. 
7KHVH¿QGLQJVVXSSRUWDUROHRI/LQWXPRULJHQHVLVDV
ZHOODV LQ WXPRUSURJUHVVLRQRIFRORQFDQFHU3UHYLRXV
studies reported that cell survival/death gene expression 
of Bcl-2 and Bax proteins, respectively, may be helpful 
LQ SUHGLFWLQJ FOLQLFDO RXWFRPH > @ SDWLHQW¶V
survival [32]. Moreover, Bcl-2/Bax ratio is implicated 





decrease of Bcl-2/Bax ratio and caspase activation [16]. In 
RUGHUWRFODULI\WKHELRORJLFDOVLJQL¿FDQFHRI/HOHYDWHG
OHYHOVLQFRORQWXPRUWLVVXHVZHHYDOXDWHGWKHH[SUHVVLRQ
levels of L3 target gene Bcl-2 and Bax. In our study, a 
FRUUHODWLRQEHWZHHQ/DQG%FO%D[ UDWLR LQSDWLHQWV
has been provided. In fact, tumor proliferation, expressed 
as the ratio of Bcl-2 mRNA copy number to that of Bax, 
ZDVIRXQGWREHLQYHUVHO\SURSRUWLRQDOWRWKHGHFUHDVHRI
/JHQHH[SUHVVLRQDQGLQFUHDVHGZLWKWXPRUJUDGHDV
previously reported [31] (Figure 1C). These clinical data 
represent the rational basis for the therapeutic targeting 
RI/,QIDFW LQWKHOLJWKRIWKHVH¿QGLQJVZHEHFDPH
LQWHUHVWHG WR XQGHUVWDQGZKHWKHU WKH UHVWRUDWLRQ RI /
could enhance 5-FU induced colon cancer cell cytoxicity. 
6LQFHPRVWFDQFHUVODFNIXQFWLRQDOS>@ZHHYDOXDWHG
the cytotoxicity and apoptotic induction potential of 
L3 in human p53 null colon cancer cells. Previously, 





L3 or 5-FU alone the proliferation rate of cells declined. 
Of note, the combination of L3 plus 5-FU resulted in 
the potentiation of the inhibitory effect of each agent on 
cell proliferation. Moreover, depletion of L3 made 5-FU 
LQHIIHFWLYHFRQ¿UPLQJRXUSUHYLXRVUHSRUWV>@ZKHUHDV
the restoration of L3 can effectively sensitize cells to 
5-FU activity (Figure 2A, 2B). The colony forming ability 
RIFHOOVWUHDWHGZLWK)8DORQHZDVSDUWLDOO\LQKLELWHG
$W GD\  RI FXOWXUH DERXW  RI )8 WUHDWHG FHOOV
KDGIRUPHGFRORQLHVVXJJHVWLQJWKDWWKHFHOOVZHUHLQD
TXLHVFHQWVWDWHSUREDEO\GHSHQGHQWRQ)8PHGLDWHGFHOO
cycle arrest. The combination of L3 plus 5-FU resulted in 
DPRUHVLJQL¿FDQWLQKLELWLRQRIWKHFRORQ\IRUPLQJDELOLW\
ZKLFKZDVQRWUHVWRUHGDIWHUGD\VLQFXOWXUH7KHVHGDWD
indicate that overexpression of L3 associated to the loss of 





the potentiation of inhibitory effect of 5-FU by promoting 
cell cycle arrest at G1 phase induced by p21. In addition, 
our results demonstrated that the cytotoxicity of L3 acts 
mainly by apoptotic cell death. In fact, the percentage of 
DSRSWRWLFFHOOVGHWHFWHGE\ÀXRUHVFHQWPLFURVFRS\DIWHU
DQQH[LQ9),7&3,VWDLQLQJZHUHLQFUHDVHGVLJQL¿FDQWO\
IROORZLQJ WUHDWPHQWZLWK/ VXJJHVWLQJ WKDW DSRSWRVLV
plays an important role in the cytotoxic effects of 















)8LS/L13V     í
)80S/L13V     í
)8+S/L13V   165 ± 18  í
)8+S/+13V   181 ± 8  í






apoptosis. Of note, the combination treatment resulted in 
DVWURQJDQGVLJQL¿FDQWLQFUHDVHRI$QQH[LQ9SRVLWLYH
FHOOV )LJXUH7KHVH UHVXOWV WRJHWKHUZLWK WKHQRWLRQ
that 5-FU sensitivity of colon cancer cells lacking p53 is 
dependent by L3 status in the cells [15], the concept to 
stimulate L3 production for a novel cancer therapy is very 
attractive. 
Over seveal years, nanotechnology is considered 
crucial to promote advances in personalized medicine 
>@DQGYHU\SURPLVLQJWRFRPELQHGLIIHUHQWGUXJVZLWK
complementary mechanisms in one delivery system 
DOORZLQJWKHLUORFDOL]DWLRQDWWKHSKDUPDFRORJLFDOWDUJHW
[36]. Poor cellular uptake and rapid degradation of 
DNA-based therapeutics necessitate the use of delivery 
systems to facilitate DNA cellular internalization. 
Adapting nanotechnologies to the delivery of DNA has 
the potential to overcome extracellular barriers that limit 
gene therapy. Nanoparticle-based DNA delivery systema 
offer several potential advantages for gene delivery to 
cancer cells including the enhancement of gene delivery 
by protecting DNA from degradation and maintaining the 
carrier at effective concentrations, extending the duration 
RIWUDQVJHQHH[SUHVVLRQ>@7RGDWHVRPH¿QGLQJVKDYH
VKRZQ F\WRWR[LF DFWLYLW\ RI WKH ZLOG W\SH SORDGHG
nanoparticles in a breast cancer cell lines [37]. 
*LYHQ WKHLU XELTXLW\ WDUJHWHG WKHUDS\ XVLQJ
USURWHLQV ZLWKRXW DGYHUVHO\ DIIHFWLQJ QRUPDO FHOOV LV
likely to prove challenging. The selective overexpression 
of certain membrane receptors on cancer cells represents 
the opportunity for targeted delivery of cytotoxic agents 
that should cause strong cytotoxicity against cancer cells, 
ZLWKPLQLPDOHIIHFWRQQRUPDOFHOOV+$LV UHSRUWHG WR
SRVVHVVVWURQJDI¿QLW\WRZDUGWKH&'RYHUH[SUHVVLQJ
cancer cells [38]. HA is nonantigenic and biocompatible 
DQG VKRZV KLJK DI¿QLW\ WRZDUG WKH UHFHSWRUV >@ ,Q
addition, CD44 receptors are overexpressed in different 
KXPDQFDQFHUFHOOVDQGWKHLUGHQVLW\LQFUHDVHVZLWKWKH
stages of cancers [38]. Therefore, HA-based targeting 
GHOLYHU\ V\VWHPV DUH H[SHFWHG WR VKRZ JUHDW SRWHQWLDO
LQ FOLQLFDO DSSOLFDWLRQV ,Q D SUHYLRXV VWXG\ ZH KDYH
developed novel polymeric nanoparticles based on a core 
of PLGA and a polymer shell of HA and PEI that represent 
a very promising system for the targeted delivery of drug 
combinations taking advantage of the shell and core 
SURSHUWLHV>@,QWKHSUHVHQWVWXG\ZHSUHSDUHG)8
loaded HA-conjugated nanoparticles to target to colon 
cancer cells. 
$Q LPSRUWDQW DVSHFW WR EH FRQVLGHUHG ZKLOH
developing a therapeutic agent is its effect on normal 
FHOOV 2XU UHVXOWV VKRZ WKDW FRPELQHG 13V ZHUH QRW
cytotoxic to normal cells and only very marginally 
LQKLELWHG QRUPDO FHOO JURZWK DV WKH\ LQGXFH FHOO F\FOH
arrest (Supplementary Figure S5) suggesting the combined 
NPs as a possible candidate to treat human cancers. Cells 
WUHDWHG ZLWK FRPELQHG 13V H[KLELWHG HI¿FLHQW FHOOXODU
uptake, expressed high and prolonged levels of L3 protein 
)LJXUHZKLFKZDVIXQFWLRQDODVLWLQGXFHGWKHOHYHOV
of its target gene p21 (Figure 8). Results from cytotoxicity 
DVVD\ VKRZ WKDW / RYHUH[SUHVVLRQ E\ FRPELQHG 13V
increase the chemosensitivity of cancer cells and are more 
HI¿FLHQW WKDQ IUHH )8 LQ VHQVLWL]LQJ S QXOO FDQFHU
cells to 5-FU (Figure 7). We also exploited the potential 
RIDSRSWRVLVXSRQWUHDWPHQWZLWKFRPELQHG13V5HVXOWV





,QFUHDVHV LQ GUXJ HIÀX[ DUH RIWHQ UHVSRQVLEOH
IRUHQKDQFHGGUXJ UHVLVWDQFHDQGDUH IUHTXHQWO\GXH WR
enhanced expression of ABC (ATP-binding cassette) 
WUDQVSRUWHU SURWHLQV VXFK DV 3JS >@ ,W KDV EHHQ
reported that the expression of P-gp is up-regulated in 
5-FU chemoresistant colon cancer cells [22]. The failure 
of 5-FU treatment of HCT 116Síícells in condition of 
pL3 silencig (MTT, TMRE and clonogenic assay and 
>@SURPSWHGXVWRLQYHVWLJDWHZKHWKHUWKHPROHFXODU
mechanisms underlying L3-mediated enhancement of 
5-FU activity involved alteration in P-gp production. 
$QDO\VLV RI 3JS H[SUHVVLRQ SUR¿OH LQGLFDWHG WKDW WKH
time-dependent increased intracellular level of L3 in 
FHOOV H[SRVHG WR FRPELQHG 13V ZDV DVVRFLDWHG WR WKH
time-dependent decrease of P-gp intracellular amount 
(Figure 8). MDR1 mRNA degradation is an important 
cellular mechanism controlling P-gp expression that 
XOWLPDWHO\DIIHFWV3JSDFWLYLW\>@2XUUHVXOWVVKRZWKDW
WKH FDQFHUVSHFL¿F FKHPRVHQVLWL]HU HIIHFW RI FRPELQHG
NPs may be partly dependent on L3 ability to negatively 
UHJXODWH0'5P51$VWDELOLW\DQGFRQVHTXHQWO\3JS
SURWHLQ H[SUHVVLRQ 7KXV WKH FRQWURO RI GUXJ HIÀX[
through the regulation of P-gp pump expression by L3 
UHSUHVHQWVDQHZPHFKDQLVPE\ZKLFKWKLVSURWHLQLVDOEH
to potentiate 5-FU activity.
Collectively, this study suggest that combined 
therapy of L3 plus 5-FU may help in developing 
therapeutic approaches for the treatment of human colon 
cancer lacking p53 and L3. 
Finally, a proof of principle on molecular-based 




$OO  SDWLHQWV RI WKH 1DWLRQDO &DQFHU ,QVWLWXWH
µ*LRYDQQL3DVFDOH¶RI1DSOHVJDYHWKHLUZULWWHQLQIRUPHG
consens according to the institutional regulations. This 





The HCT 116Síí US/¨+&7 Síí and 
1&0FHOOV&9&/B'ZHUHFXOWXUHGDVSUHYLRXVO\
UHSRUWHG >@7KH F'1$ RI /ZDV REWDLQHG E\57±




pEGFP-C1 expression vector (Clontech, Palo Alto, CA, 
USA) using the EcoRI and XbaI cloning sites [3]. The 
plasmid pEGFP-C1 (empty vector) and the fusion plasmid 
S*)3/ S/ZHUH SXUL¿HGXVLQJ4,$*(13ODVPLG
Mega Kit (Qiagen GmbH, Hilden, Germany). The pL3 
SODVPLG ZDV VHTXHQFHG WR YHULI\ WKH DFFXUDF\ RI WKH
FRQVWUXFW3ODVPLGWUDQVIHFWLRQVZHUHSHUIRUPHGLQFHOOV
DV GHVFULEHG >@7UHDWPHQWV RI FHOOVZHUH SHUIRUPHG
UHSODFLQJ WKHFXOWXUHPHGLXPZLWK WKDW FRQWDLQLQJ IUHH
5-FU or different formulations of NPs. 
57T3&5
7RWDO 51$ IURP VDPSOHV ZDV H[WUDFWHG IURP
FHOOV DV SUHYLRXVO\ GHVFULEHG >@ F'1$ ZDV
synthesized from RNA as previously described 

















7R TXDQWLI\ FKDQJHV LQPLWRFKRQGULDOPHPEUDQH











LQGLFDWHG WUHDWPHQWV FHOOVZHUH ¿[HG DQG VWDLQHGZLWK
crystal violet and counted under microscope. 
&ORQRJHQLFDVVD\




13V ORDGHG ZLWK )8 S/ RU )8S/ ZHUH
prepared by a layer-by-layer deposition method as 
SUHYLRXVO\VKRZQ>@'HWDLOVRI13SUHSDUDWLRQDQG
characterization are reported in Supplementary material 
6%ULHÀ\D3/*$QDQRFRUH5HVRPHU5*+(YRQLN
ZDV VHTXHQWLDOO\ FRDWHG ZLWK 3(,  N'D EUDQFKHG
6LJPDDQG+$N'D3K\OFDUHPLQL+$%ORRPDJH
)UHGD )8ZDV ORDGHG LQ WKH3/*$FRUHZKLOH S/
ZDV HPEHGGHG LQ WKH 3(,FRDWHG 3/*$ QDQRFRUH
&RPELQHG13VZHUH¿QDOO\IUHH]HGULHGZLWKWUHKDORVHDV
FU\RSURWHFWDQW)OXRUHVFHQW13V5KR13VZHUHSUHSDUHG
analogously using a rhodamine-labelled PLGA [47] at 
ZZZLWKUHVSHFWWRWKHWRWDO3/*$DPRXQW
Hydrodynamic diameter, polydispersity index (PI) 
DQG]HWDSRWHQWLDORI13VDIWHUHDFKSUHSDUDWLRQVWHSZHUH
determined on a ZetasizerNano Z (Malvern Instruments 
Ltd., UK). 




'1DVL PJP/ 7KH JHO HOHFWURSKRUHVLV ZDV UXQ DW
9IRUPLQVWDLQHGZLWKHWKLGLXPEURPLGHLQ7%(
buffer (Life technologies) and observed under UV light.
)8 DQG S/ ORDGLQJ ZDV DVVHVVHG RQ IUHH]H
GULHG 13V ZLWKRXW FU\RSURWHFWDQW WUHDWHG ZLWK
PHWK\OHQHFKORULGHDQGWKHQZDWHU7KHDPRXQWRI)8
LQ WKHZDWHUSKDVHZDV HYDOXDWHGE\+3/&ZKLOHS/
TXDQWL¿FDWLRQ ZDV FDUULHG RXW E\ SLFRJUHHQ '1$ NLW








 HCT 116Síí FHOOVZHUH SODWHG RQ FRYHUVOLSV DW
DGHQVLW\RIî4FHOOVSHUZHOO LQZHOOSODWHVDQG
SUHWUHDWHGZLWK IUHH+$ PJPO IRUKEHIRUH WKH
Oncotarget16www.impactjournals.com/oncotarget
DGGLWLRQRI13VKKDQGKODWHUFHOOVZHUH¿[HG
ZLWK  SDUDIRUPDOGHK\GH IRU  PLQ$IWHU ZDVKLQJ
FRYHUVOLSVZHUHPRXQWHGZLWK3%6;*OLFHURODQG
VWDLQHGZLWKGLDPLGLQRSKHQ\OLQGROH'$3,9HFWRU
Laboratories, CA, USA) to visualize the nuclei. Images 
KDYH EHHQ DFTXLUHG E\ XVLQJ WKH =HLVV &HOO 2EVHUYHU










chemiluminescence detection reagent according to the 




(PI) for 5 min (BD Biosciences, USA). Cell apoptosis 
ZDVTXDQWL¿HGE\ÀRZF\WRPHWU\RQD%')$&6&DOLEXU
%HFWRQ'LFNLQVRQ6DQ-RVH&$86$7KHGDWDZHUH
DQDO\]HG XVLQJ WKH &HOO4XHVW 3UR VRIWZDUH SDFNDJH
(Becton Dickinson, San Jose, CA, USA).
6WDWLVWLFDODQDO\VLV
Error bars represent mean ± SEM from n = 3 
ELRORJLFDOUHSOLFDWHV6WDWLVWLFDODQDO\VLVZDVSHUIRUPHG
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